Fate Therapeutics Inc (FATE)

Currency in USD
1.090
-0.060(-5.22%)
Closed·
1.080-0.010(-0.92%)
·

FATE Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.29 / -0.34
Revenue / Forecast
1.91M / 850.68K
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2025--/-0.31--/1.36M----Free Sign Up
06/2025-0.29/-0.341.91M/850.68K+14.71%+124.53%Free Sign Up
03/2025-0.32/-0.391.63M/876K+17.95%+86.07%Free Sign Up
12/2024-0.44/-0.441.86M/1.58M0%+17.72%Free Sign Up
09/2024-0.4/-0.423.07M/1.24M+4.76%+147.58%Free Sign Up
06/2024-0.33/-0.466.77M/1.33M+28.26%+409.02%Free Sign Up
03/2024-0.47/-0.481.93M/1.71M+2.08%+12.87%Free Sign Up
12/2023-0.45/-0.521.7M/1.62M+13.46%+4.94%Free Sign Up
09/2023-0.46/-0.561.94M/1.59M+17.86%+22.01%Free Sign Up
06/2023-0.54/-0.59930K/5.41M+8.47%-82.81%Free Sign Up

All numbers in USD

Fate Therapeutics Inc Earnings Call Summary for Q1/2024

  • FT819 and FT522 cell therapies show promise in autoimmune diseases and B-cell lymphoma; first lupus patient treated in FT819 Phase I study
  • FT825 enters Phase I study for solid tumors; company plans to achieve five clinical milestones in H2 2024
  • $391 million in cash and investments at Q1 2024 end; projected 2024 GAAP operating expenses of $215-230 million
  • Anticipated year-end cash balance over $270 million; consistent quarterly cash burn of $37-38 million expected
  • Company to provide updates on first lupus patients treated with FT819 by year-end; exploring additional indications for cell therapies
Last Updated: 13/05/2024, 17:58
Read Full Transcript

FAQ

What Is Fate Therapeutics's Earnings Per Share (TTM)?

The Fate Therapeutics EPS (TTM) is -1.45.

When Is The Next Fate Therapeutics Earnings Date?

Fate Therapeutics will release its next earnings report on 29 Oct 2025.

What Is Fate Therapeutics’s Revenue Forecasts For Upcoming Quarters?

Fate Therapeutics’s revenue forecast is 1.36M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.